Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,034 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Mantovani G, Macciò A, Madeddu C, Mulas C, Massa E, Astara G, Ferreli L, Mudu MC, Gramignano G, Murgia V, Lusso MR, Mocci M, Cardia A, Mura L. Mantovani G, et al. Oncol Rep. 2002 Jul-Aug;9(4):887-96. Oncol Rep. 2002. PMID: 12066227 Clinical Trial.
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.
Mantovani G, Proto E, Massa E, Mulas C, Madeddu C, Mura L, Mudu MC, Astara G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, Tore G, Mura M, Amichetti M, Maccio A. Mantovani G, et al. Int J Oncol. 2002 Feb;20(2):419-27. Int J Oncol. 2002. PMID: 11788911 Clinical Trial.
Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, Camboni P, Ferreli L, Mocci M, Perboni S, Mura L, Madeddu C, Macciò A. Mantovani G, et al. Oncol Rep. 2003 Jan-Feb;10(1):197-206. Oncol Rep. 2003. PMID: 12469169 Clinical Trial.
The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression.
Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L, Mocci M, Massa E. Mantovani G, et al. Free Radic Res. 2003 Feb;37(2):213-23. doi: 10.1080/10715760303849. Free Radic Res. 2003. PMID: 12653210
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
Mantovani G, Madeddu C, Gramignano G, Lusso MR, Mocci M, Massa E, Ferreli L, Astara G, Macciò A, Serpe R. Mantovani G, et al. J Exp Ther Oncol. 2003 Jul-Aug;3(4):205-19. doi: 10.1046/j.1359-4117.2003.01096.x. J Exp Ther Oncol. 2003. PMID: 14567291 Clinical Trial.
1,034 results